We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat... Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. Show more
Ask ADVFN Intelligence (AI)
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), September 27, 2024, 08:05 am CET / 2:05 am ET – In accordance with article 15 of...
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 27, 2024, 8.00am CET / 2.00am ET – In accordance with article 14...
Nyxoah to Participate in Upcoming Investor Conferences Mont-Saint-Guibert, Belgium – September 5, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the...
Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company’s Genio® device is complete, U.S. approval...
REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating ResultsFDA regulatory submission complete, U.S. approval on track for end of 2024U.S. commercial...
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024 Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext...
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the...
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET /...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.4465 | 5.05662514156 | 8.83 | 9.29 | 8.2 | 15904 | 8.71978009 | CS |
| 4 | 1.1765 | 14.524691358 | 8.1 | 9.29 | 7.28 | 14136 | 8.12194567 | CS |
| 12 | 1.7165 | 22.705026455 | 7.56 | 9.51 | 7.28 | 10984 | 8.29148877 | CS |
| 26 | -4.1935 | -31.1321455085 | 13.47 | 14.2 | 6.76 | 25811 | 9.10128828 | CS |
| 52 | 2.2365 | 31.7684659091 | 7.04 | 20 | 4 | 31233 | 9.91183351 | CS |
| 156 | -21.0835 | -69.4449934124 | 30.36 | 31.15 | 4 | 17981 | 9.44138287 | CS |
| 260 | -20.7435 | -69.098934044 | 30.02 | 37 | 4 | 18120 | 11.30550662 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
